TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.5888
+0.0094 (+1.61%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5795
Open0.5890
Bid0.5700 x 1000
Ask0.5995 x 1800
Day's Range0.5700 - 0.5890
52 Week Range0.5700 - 42.1000
Volume590,340
Avg. Volume496,542
Market Cap3.732M
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-13.5800
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the closing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $0.60 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 1,350,000 additional shares to cover overallotments, if any.   The Company expects to use the net proceeds from this offering to help fund Phase 3 development for its lead product candidate, TNX-102 SL, to advance the development of a recently in-licensed product candidate, TNX-1300, and for working capital and other general corporate purposes.

  • GlobeNewswire5 days ago

    Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $0.60 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The Company expects to use the net proceeds from this offering to help fund Phase 3 development for its lead product candidate, TNX-102 SL, to advance the development of a recently in-licensed product candidate, TNX-1300, and for working capital and other general corporate purposes.

  • GlobeNewswirelast month

    Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve biodefense, today announced that the China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1 to the Company on April 16, 2019. Tonix’s proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for long-term daily use at bedtime and sublingual (under-the-tongue) administration, which facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism.

  • Zacks Small Cap Researchlast month

    TNXP: Enrollment Continues for Phase 3 Trial of TNX-102 SL in PTSD…

    In March 2019, Tonix Pharmaceuticals Holding Corp. (TNXP) announced the first patient has been enrolled in the RECOVERY Phase 3 study of TNX-102 SL in patients with posttraumatic stress disorder (PTSD). The RECOVERY trial is a randomized, double blind, placebo controlled study of TNX-102 SL over 12 weeks with the primary endpoint being the Week 4 change in CAPS-5 score from baseline between TNX-102 SL and placebo-treated patients. 1) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

    NEW YORK, May 30, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at BIO 2019 International Convention

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix will present at the BIO 2019 International Convention held June 3-6, 2019, in Philadelphia, PA. A live webcast and subsequent archived recording of the Company presentation will be available under the IR Events tab of the Investor Relations section of the Tonix Pharmaceuticals website at www.tonixpharma.com.

  • How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility?
    Simply Wall St.2 months ago

    How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility?

    If you own shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) then it's worth thinking about how it...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

    Phase 2 Program Granted Breakthrough Therapy Designation by FDA  Emergency Room Visits for Cocaine Abuse Total More than 500,000 Annually in U.S. NEW YORK, May 23, 2019.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

    NEW YORK, May 21, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Announces Director Stepping Down

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced that Donald W. Landry, M.D., Ph.D., is stepping down from the Company’s Board of Directors, effective May 16, 2019. Dr. Landry has served on the Board of Directors of Tonix since 2011 and co-founded Tonix Pharmaceuticals in 2007, along with Seth Lederman, M.D., Chief Executive Officer of Tonix. “Tonix Pharmaceuticals was founded with the vision of discovering and developing pharmaceutical products to treat serious psychiatric and pain conditions,” said Dr. Landry.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense, today announced financial results for the quarter ended March 31, 2019 and an overview of recent operational highlights.  Tonix’s lead program is TNX-102 SL, or Tonmya* (cyclobenzaprine HCl sublingual tablets), for the treatment of posttraumatic stress disorder (PTSD), which was granted Breakthrough Therapy designation and which is currently being studied in a Phase 3 efficacy trial. The FDA also advised that the long-term safety exposure data from the Company’s PTSD program may be used to support a New Drug Application (NDA) for the treatment of fibromyalgia.   It is estimated that between 5-10 million adults in the U.S. are affected by fibromyalgia, of which approximately 3 million are diagnosed.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), announced on April 18, 2019 that the Company received a notice of termination, effective April 29, 2019, whereby USAMMDA is exercising its contractual right to terminate without cause the CRADA entered into on December 4, 2015 between the Company and USAMMDA relating to the development of Tonmya* or TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of Posttraumatic Stress Disorder (PTSD). The termination does not affect Tonix’s finances or the conduct of the ongoing RECOVERY trial in PTSD.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

    NEW YORK, April 22, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical.

  • Zacks Small Cap Research3 months ago

    TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway…

    On March 11, 2019, Tonix Pharmaceuticals Holding Corp. (TNXP) announced the first patient has been enrolled in the RECOVERY Phase 3 study of TNX-102 SL in patients with posttraumatic stress disorder (PTSD). The RECOVERY trial is a randomized, double blind, placebo controlled study of TNX-102 SL over 12 weeks with the primary endpoint being the Week 4 change in CAPS-5 score from baseline between TNX-102 SL and placebo-treated patients. 1) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Heating Up on Thursday

    This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.

  • Benzinga4 months ago

    What's Driving The Rally In Nanocap Biotech Tonix Pharma?

    Tonix, a biopharma company developing treatments for serious neuropsychiatric and central nervous system conditions, said it plans to expand its TNX-102 SL 5.6 mg program beyond post-traumatic stress disorder. TNX-102 SL, or Tonmya, a non-opioid, centrally acting analgesic, is the company's lead late-stage asset being evaluated for PTSD in a Phase 3 trial. The trial, dubbed RECOVERY, is actively enrolling military and civilian PTSD participants.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric and central nervous system conditions, and biological products to improve biodefense, announced today the expansion of the TNX-102 SL 5.6 mg program beyond posttraumatic stress disorder (PTSD) to include Phase 3 development for TNX-102 SL* in fibromyalgia.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

    NEW YORK, March 25, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced financial results for the fourth quarter and full year ended December 31, 2018, and an overview of recent operational highlights. “Looking forward into 2019, we are excited about the recent initiation of our new Phase 3 study of Tonmya for PTSD.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

    Investors interested in arranging a meeting with the Company’s management during either conference should contact the respective conference coordinator. Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Making Moves on Monday

    CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

  • GlobeNewswire4 months ago

    Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that the first participant was enrolled in the RECOVERY study, a new Phase 3 study of Tonmya* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD). “Tonix is committed to improving the lives of the millions who suffer from PTSD, especially military-related PTSD, and enrolling the first participant in the RECOVERY study is an important step towards achieving this goal,” said Seth Lederman, M.D., Tonix's President and Chief Executive Officer.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Surpassing Investor Expectations

    CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / When it comes to discussing healthcare stock market, it goes without saying that the success of the market is directly connected to if companies in the healthcare industry are doing their part to take care of consumers. It is the responsibility of healthcare companies to work to develop innovative treatments and care options for consumers, especially at a time where new diseases are discovered on a frequent basis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Tonix Pharmaceuticals Holding Corp (TNXP), Steller Biotechnologies Inc (SBOT), NantHealth Inc (NH) are 4 healthcare companies stepping up their game on Friday.